微芯生物管理层调整，20年老将黎建勋掌舵经营接棒总经理，董事长鲁先平退居战略层

Core Viewpoint - Micron Biomedical announced the appointment of Li Jianxun as General Manager, while Chairman Lu Xianping will focus on strategic planning and international business expansion, coinciding with the company's new drug sales and profitability turnaround [1][2] Management Changes - Li Jianxun has been with Micron Biomedical for over 20 years and has held various positions, indicating the company's recognition of his management capabilities [2] - Lu Xianping will remain as Chairman and will not affect the company's normal operations despite resigning as General Manager [2][3] Share Buyback and Financial Performance - The company completed a share buyback of 15 million yuan, reaching the plan's upper limit, intended for employee stock ownership plans or equity incentives [1] - For the first three quarters of 2025, Micron Biomedical reported revenue of 674 million yuan, a year-on-year increase of 40.12%, and a net profit of 70.77 million yuan, marking a turnaround from losses [3] Product Sales and Market Expansion - The sales of core products, Xidabena and Xiglitazone, have significantly contributed to revenue growth, with Xiglitazone's sales increasing by 136.13% year-on-year [3][5] - Xidabena has become the only oral innovative drug for DLBCL under national medical insurance, enhancing its market position [5] Strategic Focus - The management restructuring aims to optimize the management hierarchy and enhance focus on R&D and international market opportunities [3] - The company is actively pursuing global development for its innovative drugs and expanding its business team to attract interest from overseas enterprises [5]